7D36
Crystal Structure of BACE1 in complex with N-{3-[(3S)-1-amino-5-fluoro-3-methyl-3,4-dihydro-2,6-naphthyridin-3-yl]-4-fluorophenyl}-5-cyano-3-methylpyridine-2-carboxamide
7D36 の概要
| エントリーDOI | 10.2210/pdb7d36/pdb |
| 分子名称 | Beta-secretase 1, IODIDE ION, GLYCEROL, ... (5 entities in total) |
| 機能のキーワード | bace1, hydrolase |
| 由来する生物種 | Homo sapiens (Human) |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 47609.37 |
| 構造登録者 | Nakahara, K.,Mitsuoka, Y.,Kasuya, S.,Yamamoto, T.,Yamamoto, S.,Ito, H.,Kido, Y.,Kusakabe, K.I. (登録日: 2020-09-18, 公開日: 2021-07-28, 最終更新日: 2024-11-13) |
| 主引用文献 | Nakahara, K.,Mitsuoka, Y.,Kasuya, S.,Yamamoto, T.,Yamamoto, S.,Ito, H.,Kido, Y.,Kusakabe, K.I. Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central A beta reduction. Eur.J.Med.Chem., 216:113270-113270, 2021 Cited by PubMed Abstract: β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) has been pursued as a prime target for the treatment of Alzheimer's disease (AD). In this report, we describe the discovery of BACE1 inhibitors with a 1-amino-3,4-dihydro-2,6-naphthyridine scaffold. Leveraging known inhibitors 2a and 2b, we designed the naphthyridine-based compounds by removing a structurally labile moiety and incorporating pyridine rings, which showed increased biochemical and cellular potency, along with reduced basicity on the amidine moiety. Introduction of a fluorine atom on the pyridine culminated in compound 11 which had improved cellular activity as well as further reduced basicity and demonstrated a robust and sustained cerebrospinal fluid (CSF) Aβ reduction in dog. The crystal structure of compound 11 bound to BACE1 confirmed van der Waals interactions between the fluorine on the pyridine and Tyr71 in the flap. PubMed: 33765486DOI: 10.1016/j.ejmech.2021.113270 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.3 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






